1. |
Bhattarai S, Rupji M, Chao HP, et al. Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer. BJC Rep, 2024, 2(1): 87.
DOI:10.1038/s44276-024-00097-z
|
2. |
Wang M, Wei Z, Kong J, et al. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients. Diagn Pathol, 2024, 19(1): 53.
DOI:10.1186/s13000-024-01451-y
|
3. |
Xu LY, Zhao J, Wang X, et al. Non-sentinel lymph node metastases risk factors in patients with breast cancer with one or two sentinel lymph node macro-metastases. Heliyon, 2023, 9(11): e21254.
DOI:10.1016/j.heliyon.2023.e21254
|
4. |
Vemuru S, Huang J, Colborn K, et al. Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Res Treat, 2023, 200(2): 247-256.
DOI:10.1007/s10549-023-06978-0
|
5. |
He Y, Zhang J, Chen H, et al. Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients. Front Surg, 2023, 9: 1037215.
DOI:10.3389/fsurg.2022.1037215
|
6. |
Vuhahula EA, Jumanne S, Yahaya J. Expression of Ki67 as detected by MIB-1 and its association with histopathological high-risk factors among patients with retinoblastoma tumour: a cross-sectional study. BMJ Open Ophthalmol, 2022, 7(1): e000984.
DOI:10.1136/bmjophth-2022-000984
|
7. |
Zhao F, Cai C, Liu M, et al. Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model. Front Endocrinol (Lausanne), 2022, 13: 881761.
DOI:10.3389/fendo.2022.881761
|
8. |
Candás G, García A, Ocampo MD, et al. Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. Ecancermedicalscience, 2021, 15: 1162.
DOI:10.3332/ecancer.2021.1162
|
9. |
Zattarin E, Leporati R, Ligorio F, et al. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 2020, 9(12): 2644.
DOI:10.3390/cells9122644
|
10. |
Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, et al. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer, 2020, 20(1): 675.
DOI:10.1186/s12885-020-07179-4
|
11. |
Xu W, Chen X, Deng F, et al. Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review. Onco Targets Ther, 2020, 13: 5887-5899.
DOI:10.2147/OTT.S253056
|
12. |
Ding Y, Ding K, Qian H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS One, 2020, 15(4): e0231895.
DOI:10.1371/journal.pone.0231895
|
13. |
Ma H, Li L, Jia L, et al. POM121 is identified as a novel prognostic marker of oral squamous cell carcinoma. J Cancer, 2019, 10(19): 4473-4480.
DOI:10.7150/jca.33368
|